BACKGROUND

• Insulin, a protein secreted by pancreas, works to regulate blood sugar level.
• Insulin is the most commonly used drug in diabetes.
• Diabetes, separate to type I and type II, almost all patients will need to be treated with insulin.
• Diabetes is the fourth main cause of death in most developed countries.

INTRODUCTION

• The oral insulin researched and invented by the collaboration of Tsinghua University and Fosse Bio-Engineering Development Ltd is a breakthrough in insulin delivery technology in China. A lot of experts participant in the research over the past 8 years.
• We overcome the technical difficulties, such as easily degraded and difficult to be absorbed. Successfully pass the animal test and phase I clinical trial and got the result of 15% bio-availability.
• Due to the administration route of oral insulin is similar to the route
  of production of Insulin in the normal body, so this is the most
  suitable dosage form of Insulin.

FORMULATION ADVANTAGE:

	Injectable	Oral	Buccal Spray	Inhaler
Convenience
No Side Effects of Pain & Fat nacrosis
No Side Effect of Hyperinsulinism
Equivalent to normal physiological circulation

POLICY ADVANTAGE:

• Since the middle of 1980's, Chinese Government has funded oral insulin research for almost 20 years.
• Our oral insulin permitted to do phase I and phase II clinical trial continuously by SFDA. The phase I & II clinical trial had been completed, and the result has been submitted to the SFDA for approval.

MARKET OPPORTUNITY:

• We have a great chance to become the first oral insulin in World pharmaceutical market.
• The specification and production method of Oral insulin has already obtained the patent in China and US.
• The phase II clinical trial has been completed. We expect the product will contribute enormous profit to the Group in the nearest future.
• The medical expenditure on diabetic patients in United State is 140 billion US dollar in 2002, it had 40% increase when compared to the year 1997. The trend will be keep on in the coming years.
• Over 3% of the total population in China is suffering from diabetes, equivalent to more than 40 million diabetic people. The medical expenditure on diabetic patients in China has reached more than RMB 170 billion in 2002. The market will keep on increasing according to the world market trend in the coming years.